Features of the Lipid Profile in Patients with Arterial Hypertension and Cardiovascular Diseases According to Smoking Status
Oleg V. Gaisenok1, 2, Sergey Yu. Martsevich2, Marina V. Leonova3, *
Identifiers and Pagination:Year: 2018
First Page: 8
Last Page: 14
Publisher Id: TOHYPERJ-10-8
Article History:Received Date: 18/12/2017
Revision Received Date: 10/03/2018
Acceptance Date: 19/03/2018
Electronic publication date: 30/03/2018
Collection year: 2018
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Smoking is a risk factor for cardiovascular diseases. The direct influence of smoking status on the lipid profile was highlighted in patients with arterial hypertension and associated cardiovascular disease.
We aimed to evaluate lipid profile among patients related to smoking status in a registry-based cohort study.
The data of registry of National Research Сenter of Preventive Medicine were conducted. Patients filled in the special questionnaire in order to identify their smoking status, statins therapy.
274 patients were included; main nosologic disease was arterial hypertension (230 patients), 14.8% were smokers, 62.9% non-smokers, and 22.2% past-smokers. The rank analysis of variations by Kruskal-Wallis (H) test for multiple comparisons between groups revealed significant differences in lipid levels for patients according to smoking status: total cholesterol H (2, n=234) =9.119, p=0.0105; LDL-cholesterol H (2, n=225) =6.2615, p=0.0437; triglycerides H (2, n=216) =9.8485, p=0.0073; these indicators of lipid profile among non-smoking patients were lower than among smokers, these indices among past-smokers were lower than among smokers. The absence of statistically significant differences between groups was confirmed in statin therapy (χ2 =3.169, df=4, p=0.529). Logistic regression analysis was conducted to identify factors that influence achievement target lipid levels. Only 2 statistically significant signs were identified in this model: smoking (OR 0.1; 95%CI [0.13;4.87]; p=0.03) and statin therapy (OR 8.2;95%CI [-3.6; -,078]; p=0.002).
Significantly higher lipid levels have been observed in smokers compared to non-smokers in patients with arterial hypertension and associated cardiovascular disease. Smoking is a great factor disincentive to achieve target lipid levels.